doi:10.1007/s11095-013-1007-6 [PMC Full Text] [PubMed] [Crosslink] McGill MR, Sharpe MR, Williams CD, Taha M, Curry SC, Jaeschke H
For all industry stakeholderswhether operating in the compounding and telehealth space or holding approved NDAs and ANDAsthe message is clear: FDA intends to maintain a bright line between compounded and approved drugs, and companies should review their marketing materials, monitor enforcement developments, and prepare for additional waves of enforcement action
Tavor et al., Correlation between CXCR4 and homing or engraftment of acute myelogenous leukemia
neither is growth hormone itself, and neither works if the pituitary cannot respond
It is not intended to be substituted for the advice provided by your doctor or other health care professional